Vascular Cardiotoxicity of Ponatinib

Status Recruiting

Clinical Trial Summary

Pre-clinical studies suggest that the third generation tyrosine kinase inhibitor ponatinib can result in microvascular angiopathy and acceleration of atherosclerosis. This study is intended to examine for myocardial microvascular angiopathy and changes in carotid plaque in patients receiving ponatinib as part of their clinical care.

Clinical Trial Description

In this study, we will perform serial echocardiography for ventricular function, myocardial contrast echocardiography for microvascular perfusion assessment, blood analysis for myocardial injury, and carotid US for plaque or IMT progression in subjects receiving ponatinib. This series of tests is intended to provide information on the presence of clinically-evident or subclinical microvascular angiopathy and plaque acceleration. ;

Study Design

Related Conditions & MeSH terms

Cardiotoxicity

Clinical Trial Details

NCT number	NCT03930394
Study type	Observational
Source	Oregon Health and Science University
Contact	Melinda Wu, MD
Phone	503 494-4772
Email	wume@ohsu.edu
Status	Recruiting
Phase
Start date	May 15, 2019
Completion date	May 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05271162` - Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines	Phase 3
Recruiting	`NCT04262830` - Cancer Therapy Effects on the Heart
Completed	`NCT02909712` - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania	Phase 2
Recruiting	`NCT04092309` - Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation	N/A
Recruiting	`NCT04790266` - Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients
Enrolling by invitation	`NCT04305613` - Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
Not yet recruiting	`NCT05040867` - Exercise Prescription Guided by Heart Rate Variability in Breast Cancer Patients	N/A
Recruiting	`NCT05851053` - Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study
Recruiting	`NCT05992337` - New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
Enrolling by invitation	`NCT04877899` - Mazankowski Alberta Heart Institute (MAHI) EchoGo Discovery 1 Protocol
Recruiting	`NCT05096338` - Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
Recruiting	`NCT05078190` - Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
Recruiting	`NCT04632407` - Can Flaxseed Prevent Broken Hearts in Women With Breast Cancer Study?	N/A
Completed	`NCT00543062` - Staccato Prochlorperazine Thorough QT/QTc	Phase 1
Recruiting	`NCT05159479` - Defining Robust Predictors of Chemotherapy Related Cardiotoxicity
Not yet recruiting	`NCT06005259` - Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)	Phase 4
Recruiting	`NCT05406635` - Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer	N/A
Recruiting	`NCT04047901` - Effect of Physical Training in Patients With Heart Failure Caused by Chemotherapy for Cancer Treatment	N/A
Terminated	`NCT03038997` - Early Detection of Cardiac Toxicity in Childhood Cancer Survivors
Completed	`NCT01246778` - Sunitinib and Atrial Trabeculae Contractility	N/A